HP
BDTX icon

Harbourvest Partners’s Black Diamond Therapeutics BDTX Stock Holding History

Harbourvest Partners’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-9,581
Closed -$290K – 28
2020
Q3 		$290K Buy
+9,581
New +$292K 0.11% 30

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Harbourvest Partners's BDTX Position: Q4 2020 in Review

Harbourvest Partners sold out of Black Diamond Therapeutics (BDTX) in Q4 2020, closing a stake of 9,581 shares — an estimated $290K sold.

Harbourvest Partners first reported a position in BDTX in Q3 2020 and held it in 1 quarter. The position peaked at $290K in Q3 2020. 109 funds tracked by Wall St. Rank hold BDTX as of Q4 2020.

  • Harbourvest Partners reported no remaining Black Diamond Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Harbourvest Partners sold 9,581 Black Diamond Therapeutics shares in Q4 2020, an estimated $290K.
  • Harbourvest Partners first reported a position in Black Diamond Therapeutics in Q3 2020 and held it in 1 quarter.
  • Harbourvest Partners's Black Diamond Therapeutics position peaked at $290K in Q3 2020.
  • 109 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2020.

Based on Harbourvest Partners's 13F filing for Q4 2020, filed 16 Feb 2021.